Johnson & Johnson today announced positive results from the Phase 2/3 Vibrance-MG study of nipocalimab in anti-AChRa positive adolescents (aged 12 ? 17 years) living with generalized myasthenia gravis ...
Some results have been hidden because they may be inaccessible to you